HistoIndex, a pioneer in AI-driven digital pathology solutions for chronic liver disease, has announced a strategic partnership with Houston Research Institute (HRI), which will focus on metabolic dysfunction–associated steatohepatitis (MASH), supporting more precise disease assessment and clinical decision-making.
This collaboration represents a key step in HistoIndex's growing network of commercial partnerships with hepatology and gastroenterology medical centres across the United States and Europe. Through these partnerships the company will provide advanced diagnostic testing services to patients with MASH.
HRI is a leading research institute focused on conducting clinical trials in hepatology and gastroenterology, with a special emphasis on metabolic liver disease. The institute delivers high-quality research that complements the medical care that volunteers receive through their routine care centre.
Under the partnership, all four HRI medical facilities - Houston Research Institute Pasadena, Houston Research Institute Sugar Land, Houston Research Institute, and Houston Research Institute Medical Center - will have access to HistoIndex's integrated diagnostic offering, which combines expert histopathological evaluation by experienced pathologists with advanced AI-based biopsy analysis.
To complement standard-of-care histological evaluation of MASH, for steatosis, lobular inflammation, ballooning and fibrosis, HistoIndex will also offer its proprietary AI-based diagnostic test, FibroSIGHT Plus (pictured above), which delivers fully quantitative assessment of liver fibrosis in MASH liver biopsies.
"Partnering with Houston Research Institute represents a significant step forward in our mission to bring quantitative, AI-enabled pathology into MASH clinical care," said Dr Yukti Choudhury, Chief Development Officer at HistoIndex. "We provide a unique AI-enhanced diagnostic service package to our clients, and by centralising both traditional and AI-enhanced workflows, we are able to streamline turnaround times, maintain rigorous quality standards across every specimen."
From the clinical perspective, the collaboration enhances diagnostic capabilities across HRI's centres. "This partnership with HistoIndex expands our ability to offer advanced, high-quality diagnostic services to patients with MASH," commented Dr Mazen Noureddin MD MHS, Director at Houston Research Institute, and a Co-Chairman of the Board Summit and Pinnacle Clinical Research. "Integrating expert histopathology with quantitative AI-based fibrosis analysis strengthens our diagnostic capabilities and supports more informed clinical decision-making across our liver centres."